Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Dow Turns Lower; Myomo Shares Jump
Via Benzinga
Topics Stocks
Exposures US Equities
Stock Market News From Amazon, Nike, McCormick, and More
We also talk with author Nicola Twilley about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet, and Ourselves." 
Via The Motley Fool
Why Is Morphic (MORF) Stock Up 75% Today?
Morphic stock is up on Monday after the company signed a deal with Eli Lilly for the acquisition of MORF shares at $57 each in cash. 
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
What's Going On With Eli Lilly Shares Friday?
Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know. 
Via Benzinga
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Eli Lilly to acquire Morphic Holding Inc for $3.2 billion, strengthening its portfolio in chronic disease treatments. Morphic's lead program, MORF-057, targets inflammatory bowel disease, with... 
Via Benzinga
Eli Lilly Snaps Up Morphic At 79% Premium
Eli Lilly said Monday it would pay $3.2 billion to acquire an innovator in oral treatments for chronic bowel diseases. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy in July
Investors shouldn't have to think too hard about these great stocks. 
Via The Motley Fool
The Next $1 Trillion Stock? Tesla, Warren Buffett's Berkshire Hathaway In The Running
Tesla, Warren Buffett's Berkshire Hathaway are close, but this is No.1. 
Via Investor's Business Daily
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
The GLP-1 drug market for obesity treatment is expected to skyrocket to $1 trillion or more, according to Maurits Pot, founder and CEO of Tema ETFs. 
Via Benzinga
Topics ETFs
Smart Money Is Betting Big In LLY Options
Via Benzinga
Here's How Much $100 Invested In Eli Lilly and Co 15 Years Ago Would Be Worth Today
Via Benzinga
The 7 Best Under $10 Stocks to Buy in July 2024
We’re finding big opportunities in some of the best stocks under $10 a share. In fact, here are seven you may want to jump into now. 
Via InvestorPlace
Copper, Gold Stocks Sparkle, Among 5 Leaders Near Buy Points
Southern Copper and Agnico Eagle surged above early entries. 
Via Investor's Business Daily
MarketBeat Week in Review – 7/1 - 7/5
The market was mostly quiet in a holiday-shortened week; that may change next week with the latest inflation readings and the kickoff of a new earnings season 
Via MarketBeat
Topics Economy
Exposures Interest Rates
GLP-1 Treatments Such As Wegvoy, Mounjaro Cut Obesity-Related Cancer Risks, Study Finds
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce the risk of ten obesity-related cancers in type 2 diabetes patients, highlighting... 
Via Benzinga
Stock Market: S&P 500, Nasdaq Hit Highs As Tesla Soars, Rate-Cut Hopes Rise: Weekly Review
However, small caps fell. Cooling economic data raised rate-cut hopes. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
What The Quest For New Cholesterol Treatments Means For Novartis, Merck — And Patients
A number of companies are working on new drugs for high lipids, including cholesterol and triglycerides. 
Via Investor's Business Daily
Missed Out on Eli Lilly? This Much Smaller Biotech Has 2 Promising Weight Loss Assets in its Portfolio
Could Zealand Pharma be a better option for growth-oriented investors? 
Via The Motley Fool
3 Highly Rated Biotech Stocks for Your July Buy List
Discover three top-rated biotech stocks that are pushing forward the pharma and biotech revolution on Wall Street. 
Via InvestorPlace
7 High Priced Stocks That Would Benefit From a Stock Split
These companies are prime stock split candidates following moves from Nvidia and Broadcom along with other big names. 
Via InvestorPlace
Mounjaro and Zepbound Are Great, but This Is the Real Reason Why Eli Lilly Can Soar Past a $1 Trillion Valuation
Investors shouldn't assume that all of the company's future growth is already priced into the stock's valuation. 
Via The Motley Fool
The 3 Best Healthcare Stocks to Buy in July 2024
Consistent breakthroughs, improved products and relatively consistent growth make these the best healthcare stocks to buy. 
Via InvestorPlace
Forget Eli Lilly: 3 Biotech Stocks to Buy Instead
Eli Lilly is a good stock to buy, but these should be even better. 
Via The Motley Fool
S&P 500, Nasdaq 100 Climb To Record Highs As Data Fosters Rate Cut Optimism Ahead Of Fed Minutes; Gold, Bonds Rally: What's Driving Markets Wednesday?
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for rate cuts following June’s sharply lower-than-expected services sector... 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Novo Nordisk, Eli Lilly Tumble After Study Suggests Weight-Loss Drugs Can Lead To Blindness
The study comes out of a Harvard teaching hospital based in Boston. 
Via Investor's Business Daily
Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyloid plaques, shows a significant reduction in disease progression and may reduce... 
Via Benzinga
Exposures Product Safety
'Other Bets' Startup Mineral Bites The Dust In Google Cost Cutting Move
Alphabet said it's shuttering agricultural startup Mineral, one of its "Other Bets" ventures, in a cost-cutting move for Google stock. 
Via Investor's Business Daily
Top 3 Health Care Stocks That May Crash This Quarter
Via Benzinga
Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?
Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases 
Via MarketBeat
Exposures Product Safety
< Previous 1 2
...
17 18 19 20 21 22 23 24 25
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.